Eric L. Sievers

14.5k total citations · 8 hit papers
101 papers, 10.3k citations indexed

About

Eric L. Sievers is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Eric L. Sievers has authored 101 papers receiving a total of 10.3k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 34 papers in Hematology and 30 papers in Pathology and Forensic Medicine. Recurrent topics in Eric L. Sievers's work include Acute Myeloid Leukemia Research (30 papers), Lymphoma Diagnosis and Treatment (30 papers) and HER2/EGFR in Cancer Research (17 papers). Eric L. Sievers is often cited by papers focused on Acute Myeloid Leukemia Research (30 papers), Lymphoma Diagnosis and Treatment (30 papers) and HER2/EGFR in Cancer Research (17 papers). Eric L. Sievers collaborates with scholars based in United States, South Africa and Canada. Eric L. Sievers's co-authors include Peter D. Senter, Dana A. Kennedy, Nancy L. Bartlett, Andres Forero‐Torres, Anas Younes, Joseph D. Rosenblatt, John P. Leonard, Irwin D. Bernstein, Carmel M. Lynch and Joseph M. Connors and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nucleic Acids Research.

In The Last Decade

Eric L. Sievers

97 papers receiving 9.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

2012 1.0k citations Anas Younes, Ajay K. Gopal et al. Journal of Clinical Oncology profile →
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

2010 963 citations Anas Younes, Nancy L. Bartlett et al. New England Journal of Medicine profile →
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

2012 711 citations Ranjana H. Advani, Nancy L. Bartlett et al. Journal of Clinical Oncology profile →
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

2001 654 citations Eric L. Sievers, Mark S. Berger et al. Journal of Clinical Oncology profile →
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia

2001 632 citations Eric L. Sievers et al. Journal of Clinical Oncology profile →
Antibody-Drug Conjugates in Cancer Therapy

2012 596 citations Eric L. Sievers, Peter D. Senter profile →
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

2012 577 citations Peter D. Senter, Eric L. Sievers profile →
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

2015 477 citations Craig H. Moskowitz, Auayporn Nademanee et al. The Lancet profile →

Peers

Countries citing papers authored by Eric L. Sievers

Since Specialization

Citations

This map shows the geographic impact of Eric L. Sievers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric L. Sievers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric L. Sievers more than expected).

Fields of papers citing papers by Eric L. Sievers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric L. Sievers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric L. Sievers. The network helps show where Eric L. Sievers may publish in the future.

Co-authorship network of co-authors of Eric L. Sievers

This figure shows the co-authorship network connecting the top 25 collaborators of Eric L. Sievers. A scholar is included among the top collaborators of Eric L. Sievers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric L. Sievers. Eric L. Sievers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment of Acute Myocardial Infarction and Cardiogenic Shock: Outcomes of the RECOVER III Postapproval Study by Society of Cardiovascular Angiography and Interventions Shock Stage 2024 ·Journal of the American Heart Association ·Ivan Hanson, (unknown), (unknown), (unknown), (unknown), Simon Dixon, Perwaiz Meraj, Eric L. Sievers, Michael J. Johnson, David Wohns, (unknown), Navin K. Kapur, Cindy L. Grines, Daniel Burkhoff, Mark Anderson, Alexandra J. Lansky, Srihari S. Naidu, Mir B. Basir, William W. O’Neill	3
2	Inundative, Dry-Powder, Inhaled Measles Vaccination to Prevent Deaths of Young Children in War-torn Regions 2023 ·Open Forum Infectious Diseases ·Benjamín L. Sievers, Robert E. Sievers, Eric L. Sievers	0
3	The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides 2021 ·Cancer Immunology Immunotherapy ·Oleg Kruglov, Lisa D. Johnson, (unknown), Kimberly R. Jordan, Robert A. Uger, Mark Wong, Eric L. Sievers, Yaping Shou, Oleg E. Akilov	8
4	Primary meningitis due to Fusobacterium nucleatum successfully treated with ceftriaxone in a healthy adult male 2019 ·IDCases ·(unknown), (unknown), Eric L. Sievers, (unknown), (unknown)	2
5	A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 Do Not Eat Signal 2017 ·Blood ·Christiane Querfeld, John A. Thompson, Matthew H. Taylor, Raju Pillai, Lisa D. Johnson, (unknown), Penka S. Petrova, Robert A. Uger, (unknown), Eric L. Sievers, Oleg E. Akilov	15
6	Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial breakdown → 2015 ·The Lancet ·Craig H. Moskowitz, Auayporn Nademanee, Tamás Masszi, Edward Agura, Jerzy Hołowiecki, Muneer H. Abidi, Andy I. Chen, Patrick J. Stiff, Alessandro M. Gianni, Angelo Michele Carella, Dzhelil Osmanov, Veronika Bachanová, John Sweetenham, Anna Sureda, Dirk Huebner, Eric L. Sievers, Andy Chi, Emily K. Larsen, Naomi Hunder, Jan Walewski	477
7	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma breakdown → 2012 ·Journal of Clinical Oncology ·Anas Younes, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, Kerry J. Savage, Radhakrishnan Ramchandren, Nancy L. Bartlett, Bruce D. Cheson, Sven de Vos, Andres Forero‐Torres, Craig H. Moskowitz, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Dana A. Kennedy, Eric L. Sievers, Robert Chen	1014
8	A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies 2011 ·Clinical Cancer Research ·Michelle A. Fanale, Andres Forero‐Torres, Joseph D. Rosenblatt, Ranjana H. Advani, Anna R. Franklin, Dana A. Kennedy, Tae Hyung Han, Eric L. Sievers, Nancy L. Bartlett	160
9	Soluble interleukin‐2 receptor α activation in a Children's Oncology Group randomized trial of interleukin‐2 Therapy for Pediatric Acute Myeloid Leukemia 2011 ·Pediatric Blood & Cancer ·Beverly J. Lange, Richard K. Yang, Jacek Gan, (unknown), Eric L. Sievers, Todd A. Alonzo, Robert B. Gerbing, Paul M. Sondel	7
10	Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate 2010 ·Clinical Cancer Research ·Nicole M. Okeley, Jamie B. Miyamoto, Xinqun Zhang, Russell J. Sanderson, Dennis R. Benjamin, Eric L. Sievers, Peter D. Senter, Stephen C. Alley	291
11	5-Azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia 2010 ·mAbs ·May Kung Sutherland, Changpu Yu, Martha E. Anderson, Weiping Zeng, Nico van Rooijen, Eric L. Sievers, Iqbal S. Grewal, Che‐Leung Law	24
12	Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas breakdown → 2010 ·New England Journal of Medicine ·Anas Younes, Nancy L. Bartlett, John P. Leonard, Dana A. Kennedy, Carmel M. Lynch, Eric L. Sievers, Andres Forero‐Torres	963
13	Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL 2006 ·Blood ·April Chiu, Weifeng Xu, Bing He, Stacey R. Dillon, Jane A. Gross, Eric L. Sievers, Xugang Qiao, Paul A Santini, Elizabeth Hyjek, (unknown), Ethel Cesarman, Amy Chadburn, Daniel M. Knowles, Andrea Cerutti	157
14	Native Antibody and Antibody-Targeted Chemotherapy for Acute Myeloid Leukemia 2004 ·Advances in pharmacology ·Eric L. Sievers	2
15	Pharmacogenetics of Gemtuzumab-Associated Hepatic Sinusoidal Occlusion Syndrome after Hematopoietic Stem Cell Transplant 2003 ·Acta Haematologica ·Richard Aplenc, Anil Vachani, Peggy Han, (unknown), Eric L. Sievers	2
16	Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia 2002 ·Blood ·Eric L. Sievers	155
17	Preliminary report of an ascending dose study of gemtuzumab ozogamicin (mylotarg™, cma-676) in pediatric patients with acute myeloid leukemia 2000 ·Blood ·Eric L. Sievers, R.J. Arceci, Janet Franklin, Beverly J. Lange, Kevin Shannon, (unknown), Mark S. Berger, (unknown), (unknown)	10
18	Children's cancer group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia. 2000 ·PubMed ·Eric L. Sievers, (unknown), Sondel Pm, (unknown), Jing Gan, (unknown), Wen Liu‐Mares, Feig Sa	15
19	Prediction of Relapse of Pediatric Acute Myeloid Leukemia by Use of Multidimensional Flow Cytometry 1996 ·JNCI Journal of the National Cancer Institute ·Eric L. Sievers, Beverly J. Lange, Jonathan D. Buckley, Franklin O. Smith, D. Wells, (unknown), Keith Shults, I D Bernstein, Michael R. Loken	67
20	Long-term survival of a patient with primary sellar choriocarcinoma with pulmonary metastases: A case report 1996 ·Medical and Pediatric Oncology ·Eric L. Sievers, Mitchel S. Berger, J. Russell Geyer	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact